Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Apr 2022
Apr 2022
Historique:
received:
05
05
2021
accepted:
28
10
2021
pubmed:
19
11
2021
medline:
24
3
2022
entrez:
18
11
2021
Statut:
ppublish
Résumé
Prognosis in pancreatic ductal adenocarcinoma (PDAC) remains poor despite improved systemic therapies and surgical techniques. The identification of biomarkers to advance insight in tumor biology and achieve better individualized prognostication could help improve outcomes. Our aim was to elucidate the prognostic role of the four main driver mutations (KRAS, TP53, SMAD4, CDKN2A) and their combinations in resected PDAC. A retrospective analysis was conducted utilizing the cBioPortal database and National Cancer Institute's Cancer Genomic Atlas (TCGA) on patients in whom next-generation sequencing was performed on upfront resected PDAC from 2012 to 2020. Multivariable Cox regression was implemented to elucidate risk-adjusted predictors of overall (OS) and recurrence-free survival (RFS). Results were validated employing a Johns Hopkins Hospital (JHH) cohort.' In the discovery cohort (n = 587), increased number of mutated driver genes was associated with worse OS (p = 0.047). Specifically, patients with mutations in ≥ 2 driver genes had worse OS than ≤ 1 mutated gene (18.2 versus 32.3 months, p = 0.033). Co-occurrence of mutant (mt)KRAS p.G12D with mtTP53 (median OS, 25.9 months) conferred better prognosis than co-occurrence of other mtKRAS variants (p.G12V/R/other) with mtTP53 (median OS, 16.9 months, p = 0.038). The findings were validated using a JHH cohort. Multivariable risk-adjustment found co-occurrence of mtKRAS p.G12D with mtTP53 to be an independent predictor of beneficial OS and RFS [HR (95% CI): 0.18 (0.03-0.81) and 0.31 (0.11-0.89) respectively]. In chemo-naïve resected PDAC, combinations of mutations in the four driver genes are associated with prognosis. In patients with combined mtKRAS and mtTP53, KRAS p.G12D variant confers a better OS and RFS.
Sections du résumé
BACKGROUND
BACKGROUND
Prognosis in pancreatic ductal adenocarcinoma (PDAC) remains poor despite improved systemic therapies and surgical techniques. The identification of biomarkers to advance insight in tumor biology and achieve better individualized prognostication could help improve outcomes. Our aim was to elucidate the prognostic role of the four main driver mutations (KRAS, TP53, SMAD4, CDKN2A) and their combinations in resected PDAC.
PATIENTS AND METHODS
METHODS
A retrospective analysis was conducted utilizing the cBioPortal database and National Cancer Institute's Cancer Genomic Atlas (TCGA) on patients in whom next-generation sequencing was performed on upfront resected PDAC from 2012 to 2020. Multivariable Cox regression was implemented to elucidate risk-adjusted predictors of overall (OS) and recurrence-free survival (RFS). Results were validated employing a Johns Hopkins Hospital (JHH) cohort.'
RESULTS
RESULTS
In the discovery cohort (n = 587), increased number of mutated driver genes was associated with worse OS (p = 0.047). Specifically, patients with mutations in ≥ 2 driver genes had worse OS than ≤ 1 mutated gene (18.2 versus 32.3 months, p = 0.033). Co-occurrence of mutant (mt)KRAS p.G12D with mtTP53 (median OS, 25.9 months) conferred better prognosis than co-occurrence of other mtKRAS variants (p.G12V/R/other) with mtTP53 (median OS, 16.9 months, p = 0.038). The findings were validated using a JHH cohort. Multivariable risk-adjustment found co-occurrence of mtKRAS p.G12D with mtTP53 to be an independent predictor of beneficial OS and RFS [HR (95% CI): 0.18 (0.03-0.81) and 0.31 (0.11-0.89) respectively].
CONCLUSION
CONCLUSIONS
In chemo-naïve resected PDAC, combinations of mutations in the four driver genes are associated with prognosis. In patients with combined mtKRAS and mtTP53, KRAS p.G12D variant confers a better OS and RFS.
Identifiants
pubmed: 34792696
doi: 10.1245/s10434-021-11081-z
pii: 10.1245/s10434-021-11081-z
doi:
Substances chimiques
Biomarkers, Tumor
0
KRAS protein, human
0
TP53 protein, human
0
Tumor Suppressor Protein p53
0
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2720-2731Informations de copyright
© 2021. Society of Surgical Oncology.
Références
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33. https://doi.org/10.3322/caac.21654 .
doi: 10.3322/caac.21654
pubmed: 33433946
Strobel O, Neoptolemos J, Jäger D, Büchler MW. Optimizing the outcomes of pancreatic cancer surgery. Nat Rev Clin Oncol. 2019;16(1):11–26. https://doi.org/10.1038/s41571-018-0112-1 .
doi: 10.1038/s41571-018-0112-1
pubmed: 30341417
Conroy T, Hammel P, Hebbar M, et al. Folfirinox or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395–406. https://doi.org/10.1056/nejmoa1809775 .
doi: 10.1056/nejmoa1809775
pubmed: 30575490
Kinny-Köster B, van Oosten F, Habib JR, et al. Mesoportal bypass, interposition graft, and mesocaval shunt: surgical strategies to overcome superior mesenteric vein involvement in pancreatic cancer. Surgery. 2020;168(6):1048–55. https://doi.org/10.1016/j.surg.2020.07.054 .
doi: 10.1016/j.surg.2020.07.054
pubmed: 32951905
Habib JR, Kinny-Köster B, vanOosten F, et al. Periadventitial dissection of the superior mesenteric artery for locally advanced pancreatic cancer: surgical planning with the “halo sign” and “string sign.” Surgery. 2020. https://doi.org/10.1016/j.surg.2020.08.031 .
doi: 10.1016/j.surg.2020.08.031
pubmed: 33036782
Gemenetzis G, Groot VP, Yu J, et al. Circulating tumor cells dynamics in pancreatic adenocarcinoma correlate with disease status: results of the prospective CLUSTER Study. Ann Surg. 2018;268(3):408–20. https://doi.org/10.1097/SLA.0000000000002925 .
doi: 10.1097/SLA.0000000000002925
pubmed: 30080739
Poruk KE, Valero V, Saunders T, et al. Circulating tumor cell phenotype predicts recurrence and survival in pancreatic adenocarcinoma. Ann Surg. 2016;264(6):1073–81. https://doi.org/10.1097/SLA.0000000000001600 .
doi: 10.1097/SLA.0000000000001600
pubmed: 26756760
Habib JR, Yu J, Yin L. Pancreatic ductal adenocarcinoma: the role of circulating tumor DNA. J Pancreatol. 2019;2(3):72–5.
doi: 10.1097/JP9.0000000000000021
Shen GQ, Aleassa EM, Walsh RM, Morris-Stiff G. Next-generation sequencing in pancreatic cancer. Pancreas. 2019;48(6):739–48. https://doi.org/10.1097/MPA.0000000000001324 .
doi: 10.1097/MPA.0000000000001324
pubmed: 31206465
Cicenas J, Kvederaviciute K, Meskinyte I, et al. KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 mutations in pancreatic cancer. Cancers. 2017. https://doi.org/10.3390/cancers9050042 .
doi: 10.3390/cancers9050042
pubmed: 29267206
pmcid: 5789351
Makohon-Moore A, Iacobuzio-Donahue CA. Pancreatic cancer biology and genetics from an evolutionary perspective. Nat Rev Cancer. 2016;16(9):553–65. https://doi.org/10.1038/nrc.2016.66.Pancreatic .
doi: 10.1038/nrc.2016.66.Pancreatic
pubmed: 27444064
pmcid: 5739515
Yachida S, White CM, Naito Y, et al. Clinical significance of the genetic landscape of pancreatic cancer and implications for identification of potential long term survivors. Clin Cancer Res. 2013;18(22):6339–47. https://doi.org/10.1158/1078-0432.CCR-12-1215.Clinical .
doi: 10.1158/1078-0432.CCR-12-1215.Clinical
McIntyre CA, Lawrence SA, Richards AL, et al. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma. Cancer. 2020;126(17):3939–49. https://doi.org/10.1002/cncr.33038 .
doi: 10.1002/cncr.33038
pubmed: 32573775
Buscail L, Bournet B, Cordelier P. Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer. Nat Rev Gastroenterol Hepatol. 2020;17(3):153–68. https://doi.org/10.1038/s41575-019-0245-4 .
doi: 10.1038/s41575-019-0245-4
pubmed: 32005945
Kang CM, Hwang HK, Park J, et al. Maximum standard uptake value as a clinical biomarker for detecting loss of SMAD4 expression and early systemic tumor recurrence in resected left-sided pancreatic cancer. Medicine. 2016;95(17):1–6. https://doi.org/10.1097/MD.0000000000003452 .
doi: 10.1097/MD.0000000000003452
Schlitter AM, Segler A, Steiger K, et al. Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): identification of prognostic subtypes. Sci Rep. 2016;2017(7):1–12. https://doi.org/10.1038/srep41064 .
doi: 10.1038/srep41064
Rutering J, Ilmer M, Recio A, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2016;5(6):1–8. https://doi.org/10.1038/nm.4333.Mutational .
doi: 10.1038/nm.4333.Mutational
Hyman DM, Piha-paul SA, Won H, et al. HER kinase inhibition in patients with HER2- and HER3-mutant cancers. Nature. 2018;554(7691):189–94. https://doi.org/10.1038/nature25475.HER .
doi: 10.1038/nature25475.HER
pubmed: 29420467
pmcid: 5808581
Samstein RM, Lee C-H, Shoustan A, et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat Genet. 2019;51(12):202–6. https://doi.org/10.1038/s41588-018-0312-8.Corresponding .
doi: 10.1038/s41588-018-0312-8.Corresponding
pubmed: 30643254
pmcid: 6365097
Rosen EY, Goldman DA, Hechtman JF, et al. TRK fusions are enriched in cancers with uncommon histologies and the absence of canonical driver mutations. Clin Cancer Res. 2020;26(7):1624–32. https://doi.org/10.1158/1078-0432.CCR-19-3165.TRK .
doi: 10.1158/1078-0432.CCR-19-3165.TRK
pubmed: 31871300
Bolton KL, Ptashkin RN, Gao T, et al. Cancer therapy shapes the fitness landscape of clonal hematopoiesis. Nat Genet. 2020;52(11):1219–26. https://doi.org/10.1038/s41588-020-00710-0 .
doi: 10.1038/s41588-020-00710-0
pubmed: 33106634
pmcid: 7891089
Robinson DR, Wu Y-M, Lonigro RJ, et al. Integrative clinical genomics of metastatic cancer. Nature. 2017;548(7667):297–303. https://doi.org/10.1038/nature23306.Integrative .
doi: 10.1038/nature23306.Integrative
pubmed: 28783718
pmcid: 5995337
Miao D, Margolis CA, Vokes NI, et al. Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors. Nat Genet. 2018;50(9):1271–81.
doi: 10.1038/s41588-018-0200-2
Biankin AV, Waddell N, Kassahn KS, et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature. 2012;491(7424):399–405. https://doi.org/10.1038/nature11547.Pancreatic .
doi: 10.1038/nature11547.Pancreatic
pubmed: 23103869
pmcid: 3530898
Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature. 2016;531(7592):47–52. https://doi.org/10.1038/nature16965 .
doi: 10.1038/nature16965
pubmed: 26909576
Ding D, Javed AA, Cunningham D, et al. Challenges of the current precision medicine approach for pancreatic cancer: a single institution experience between 2013 and 2017. Cancer Lett. 2021;497:221–8. https://doi.org/10.1016/j.canlet.2020.10.039 .
doi: 10.1016/j.canlet.2020.10.039
pubmed: 33127389
Amin MB, Greene FL, Edge SB, et al. The Eighth Edition AJCC Cancer Staging Manual: continuing to build a bridge from a population-based to a more “personalized” approach to cancer staging. CA Cancer J Clin. 2017;67(2):93–9. https://doi.org/10.3322/caac.21388 .
doi: 10.3322/caac.21388
pubmed: 28094848
Rahib L, Smith BD, Aizenberg R, et al. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74(11):2913–21. https://doi.org/10.1158/0008-5472.CAN-14-0155 .
doi: 10.1158/0008-5472.CAN-14-0155
pubmed: 24840647
Hong SM, Park JY, Hruban RH, Goggins M. Molecular signatures of pancreatic cancer. Arch Pathol Lab Med. 2011;135(6):716–27. https://doi.org/10.1043/2010-0566-RA.1 .
doi: 10.1043/2010-0566-RA.1
pubmed: 21631264
pmcid: 3107523
Hayashi H, Kohno T, Ueno H, et al. Utility of assessing the number of mutated KRAS, CDKN2A, TP53, and SMAD4 genes using a targeted deep sequencing assay as a prognostic biomarker for pancreatic cancer. Pancreas. 2017;46(3):335–40. https://doi.org/10.1097/MPA.0000000000000760 .
doi: 10.1097/MPA.0000000000000760
pubmed: 28099251
Qian ZR, Rubinson DA, Nowak JA, et al. Association of alterations in main driver genes with outcomes of patients with resected pancreatic ductal adenocarcinoma. JAMA Oncol. 2018;4(3):3–4. https://doi.org/10.1001/jamaoncol.2017.3420 .
doi: 10.1001/jamaoncol.2017.3420
Zarkavelis G, Kotoula V, Kolliou GA, et al. 2019 Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-paclitaxel-based chemotherapy or agents targeting the EGFR axis: A retrospective analysis of the Hellenic Cooperative Oncology Group (HeCO. ESMO Open.;4(5). https://doi.org/10.1136/esmoopen-2019-000525
Cordenonsi M, Dupont S, Maretto S, et al. Links between tumor suppressors: p53 is required for TGF-β gene responses by cooperating with Smads. Cell. 2003;113(3):301–14. https://doi.org/10.1016/S0092-8674(03)00308-8 .
doi: 10.1016/S0092-8674(03)00308-8
pubmed: 12732139
Cordenonsi M, Montagner M, Adorno M, et al. Integration of TGF-B and Ras/MAPK signaling through p53 phosphorylation. Science (80-). 2007;315:840–4.
doi: 10.1126/science.1135961
Kretzschmar M, Doody J, Timokhina I, Massagué J. A mechanism of repression of TGFfβ/Smad signaling by oncogenic Ras. Genes Dev. 1999;13(7):804–16. https://doi.org/10.1101/gad.13.7.804 .
doi: 10.1101/gad.13.7.804
pubmed: 10197981
pmcid: 316599
Kim MP, Li X, Deng J, et al. Oncogenic KRAS recruits an expansive transcriptional network through mutant p53 to drive pancreatic cancer metastasis. Cancer Discov. 2021. https://doi.org/10.1158/2159-8290.cd-20-1228 .
doi: 10.1158/2159-8290.cd-20-1228
pubmed: 34933901
pmcid: 8758513
Canon J, Rex K, Saiki AY, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575(7781):217–23. https://doi.org/10.1038/s41586-019-1694-1 .
doi: 10.1038/s41586-019-1694-1
pubmed: 31666701
Fakih M, O’Neil B, Price TJ, et al. Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRAS G12C inhibitor, in advanced solid tumors. J Clin Oncol. 2019;37(15):3003–3003. https://doi.org/10.1200/jco.2019.37.15_suppl.3003 .
doi: 10.1200/jco.2019.37.15_suppl.3003